Getting semaglutide prescribed starts with a medical evaluation, either through your primary care doctor or a telehealth platform, where a provider confirms you meet the clinical criteria for the medication. The process is straightforward if you qualify, but the specific steps depend on whether you’re seeking it for type 2 diabetes or weight loss, since the two uses have different brand names, different eligibility rules, and very different insurance landscapes.
Which Version You Qualify For
Semaglutide is sold under several brand names, and each one is FDA-approved for specific conditions. Understanding which applies to you determines the entire path forward.
For type 2 diabetes, Ozempic (injection) and Rybelsus (oral tablet) are approved to improve blood sugar control in adults and to reduce the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes who are at high risk for those events. Neither is approved for pediatric patients.
For weight loss, Wegovy is approved for adults with obesity (BMI of 30 or higher) or adults with overweight (BMI of 27 to 29.9) who also have at least one weight-related health condition such as high blood pressure, high cholesterol, or type 2 diabetes. Wegovy is also approved for adolescents aged 12 and older with obesity.
If your BMI falls below 27, or you’re between 27 and 30 without a qualifying comorbidity, you won’t meet the prescribing criteria for the weight loss indication.
Choosing a Provider
Your primary care doctor is the most natural starting point. They already know your medical history, current medications, and any conditions that might affect whether semaglutide is safe for you. Endocrinologists, obesity medicine specialists, and physician nutrition specialists also commonly prescribe it, particularly for patients with complex metabolic profiles.
Telehealth platforms are another legitimate route. Most begin with a health intake questionnaire covering your medical history, current medications, prior experience with similar drugs, and your goals. A licensed provider then reviews your information and may follow up via video call, phone, or secure messaging. If they determine you’re a good candidate, they write the prescription and guide you on next steps. Any platform that offers semaglutide without requiring a consultation or prescription is not operating legitimately.
What Happens During the Medical Evaluation
Before prescribing semaglutide, your provider will typically order baseline blood work. This usually includes fasting blood sugar and HbA1c (a measure of average blood sugar over three months), kidney function tests, liver enzyme levels, a thyroid panel, a complete cholesterol panel, and a complete blood count. These results establish a starting point so your provider can track how the medication affects your body over time.
Your provider will also screen for conditions that rule out semaglutide entirely. If you or a blood relative has a history of a specific type of thyroid cancer called medullary thyroid carcinoma, or a rare condition called Multiple Endocrine Neoplasia syndrome type 2 (which causes tumors in multiple glands), your doctor will likely not prescribe it. A personal history of pancreatitis is another factor providers evaluate carefully.
Getting Insurance to Cover It
Insurance coverage for semaglutide varies dramatically depending on the indication and your plan. For type 2 diabetes, most commercial insurers cover Ozempic or Rybelsus, though they may require prior authorization proving you’ve tried other diabetes medications first.
For weight loss, coverage is far less predictable. Many insurers still classify weight management drugs as optional and exclude them. Even among plans that do cover Wegovy, prior authorization is common. Your provider typically needs to document your BMI, qualifying comorbidities, and sometimes evidence of previous weight loss attempts through diet, exercise, or other interventions.
Government programs are especially restrictive. Medi-Cal, for example, removed Wegovy from its covered drug list for weight loss indications as of January 2026, along with several other medications in the same class. Medicare Part D coverage for weight management drugs has been limited historically, though this continues to evolve. If your insurer denies coverage, your provider can often submit an appeal with additional clinical documentation.
Costs Without Full Coverage
If you have commercial insurance, the manufacturer offers a savings program that brings the cost of Wegovy down to $25 per month for a 28-day supply of injections or a 30-day supply of the oral version. You need a valid prescription, active commercial insurance, and you cannot be enrolled in Medicare, Medicaid, or other government programs.
Without insurance, out-of-pocket costs are significantly higher. The manufacturer has offered cash-pay pricing for Wegovy injections at $199 per month for the first two months on lower doses, then $349 per month after that. The oral form has been available at $149 per month for lower doses. These prices and their availability windows change, so check the manufacturer’s website for current offers.
Avoiding Compounded Versions
You may see cheaper semaglutide advertised through compounding pharmacies or online sellers. The FDA has moved to restrict compounded versions of semaglutide, proposing to exclude it from the list of drugs that large-scale compounding facilities can produce. Compounded medications don’t go through the same safety, purity, and potency testing as FDA-approved products. The concentration can vary between batches, and contamination risks are real. Sticking with FDA-approved brand-name versions prescribed through a licensed provider is the safest path.
What to Expect After the Prescription
Semaglutide prescriptions start at a low dose and increase gradually over several months. This slow ramp-up minimizes gastrointestinal side effects like nausea, which are most common in the early weeks. Your provider will schedule follow-up appointments to check how you’re tolerating the medication, repeat blood work at intervals, and adjust the dose on a set timeline. For weight management with Wegovy, the clinical trials that established its effectiveness ran for 68 weeks, so plan on this being a longer-term commitment rather than a short course of treatment.
If your initial provider is hesitant to prescribe or unfamiliar with the medication, asking for a referral to an obesity medicine specialist or endocrinologist is reasonable. These specialists manage semaglutide prescriptions routinely and can navigate the prior authorization process more efficiently.